MANGALAMPharmaceuticals
Mangalam Drugs and Organics Ltd — Cash Flow Statement
₹27.15
-4.91%
Mangalam Drugs and Organics Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 22.39 Cr | -7.92 Cr | 11.61 Cr | -1.96 Cr | — |
| Capital Expenditure | -20.20 Cr | -11.83 Cr | -27.91 Cr | -27.67 Cr | — |
| End Cash Position | 2.59 Cr | 1.18 Cr | 2.68 Cr | 1.95 Cr | — |
| Beginning Cash Position | 1.18 Cr | 3.87 Cr | 1.95 Cr | 0.58 Cr | — |
| Changes In Cash | 1.41 Cr | -2.69 Cr | 0.73 Cr | 1.36 Cr | — |
| Financing Cash Flow | -21.71 Cr | 5.23 Cr | -16.62 Cr | 2.98 Cr | — |
| Interest Paid Cff | -14.93 Cr | -7.26 Cr | -12.75 Cr | -11.16 Cr | — |
| Net Issuance Payments Of Debt | -6.78 Cr | 12.49 Cr | -3.87 Cr | 14.14 Cr | — |
| Net Short Term Debt Issuance | -2.66 Cr | 16.94 Cr | 2.47 Cr | -4.09 Cr | — |
| Net Long Term Debt Issuance | -4.12 Cr | -4.45 Cr | -6.34 Cr | 18.23 Cr | — |
| Investing Cash Flow | -19.47 Cr | -11.83 Cr | -22.17 Cr | -27.33 Cr | — |
| Dividends Received Cfi | 4000.00 | 4000.00 | 5000.00 | 5000.00 | — |
| Net Investment Purchase And Sale | 0.00 | -1000.00 | 0.00 | 0.21 Cr | — |
| Net PPE Purchase And Sale | -19.47 Cr | -11.83 Cr | -22.17 Cr | -27.53 Cr | — |
| Sale Of PPE | 0.73 Cr | 50000.00 | 5.74 Cr | 0.14 Cr | — |
| Purchase Of PPE | -20.20 Cr | -11.83 Cr | -27.91 Cr | -27.67 Cr | — |
| Operating Cash Flow | 42.59 Cr | 3.91 Cr | 39.52 Cr | 25.71 Cr | — |
| Taxes Refund Paid | -0.08 Cr | -0.09 Cr | 0.03 Cr | -8.81 Cr | — |
| Change In Working Capital | 7.29 Cr | -13.91 Cr | 13.36 Cr | -15.59 Cr | — |
| Change In Other Current Liabilities | 4.01 Cr | -25.12 Cr | 1.31 Cr | 17.07 Cr | — |
| Change In Other Current Assets | 4.92 Cr | 12.99 Cr | 1.12 Cr | 4.05 Cr | — |
| Change In Payable | 24.99 Cr | -19.90 Cr | 42.53 Cr | 11.15 Cr | — |
| Change In Prepaid Assets | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Change In Inventory | -15.16 Cr | 16.89 Cr | -20.36 Cr | -58.52 Cr | — |
| Change In Receivables | -11.06 Cr | -0.02 Cr | -0.05 Cr | 7.80 Cr | — |
| Other Non Cash Items | 14.93 Cr | 7.26 Cr | 12.75 Cr | 11.16 Cr | — |
| Depreciation And Amortization | 16.61 Cr | 7.49 Cr | 10.99 Cr | 10.25 Cr | — |
| Depreciation | 16.61 Cr | 7.49 Cr | 10.99 Cr | 10.25 Cr | — |
| Pension And Employee Benefit Expense | -0.87 Cr | -0.88 Cr | 0.18 Cr | 0.17 Cr | — |
| Gain Loss On Investment Securities | -4000.00 | -4000.00 | -5000.00 | 0.62 Cr | — |
| Gain Loss On Sale Of PPE | -0.07 Cr | 0.07 Cr | 33000.00 | 0.17 Cr | — |
| Net Income From Continuing Operations | 4.79 Cr | 3.97 Cr | 2.21 Cr | 27.73 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | 2000.00 | 1000.00 | — | -1000.00 |
| Net Other Financing Charges | — | 1000.00 | — | -1000.00 | — |
| Issuance Of Capital Stock | — | — | 0.00 | 0.00 | 0.00 |
| Net Common Stock Issuance | — | — | 0.00 | 0.00 | 0.00 |
| Common Stock Issuance | — | — | 0.00 | 0.00 | 0.00 |
| Provisionand Write Offof Assets | — | — | — | 0.10 Cr | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Mangalam Drugs and Organics Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.